All In Biotech

Drug Trial Radar · NCT07020533

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Feb 14, 2030

Study completion Feb 14, 2030

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.

Conditions

  • Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Hematopoietic and Lymphatic System Neoplasm
  • Hodgkin Lymphoma
  • Lymphoblastic Lymphoma
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Neoplasm
  • Non-Hodgkin Lymphoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Electronic Health Record ReviewOther

    Ancillary studies

  • Haploidentical Hematopoietic Cell TransplantationProcedure

    Undergo HCT

  • LetermovirDrug

    Given IV or PO

  • Multi-peptide CMV-Modified Vaccinia Ankara VaccineBiological

    Given IM

  • Myeloablative ConditioningProcedure

    Receive myeloablative conditioning

  • PheresisProcedure

    Undergo apheresis

  • Recombinant Granulocyte Colony-Stimulating FactorBiological

    Given G-CSF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cytomegalovirus (CMV) reactivation prompting antiviral therapyTime frame: From day 0 to day 100 post-hematopoietic stem cell transplant (HCT)
  2. CMV diseaseTime frame: From day 0 to day 100 post-HCT

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.